Dummer Reinhard, Urosevic Mirjana, Kempf Werner, Kazakov Dmitry, Burg Günter
Department of Dermatology, University Hospital Zurich, Zurich, Switzerland.
Dermatology. 2003;207(1):116-8. doi: 10.1159/000070962.
Imiquimod is a topical immune response modifier that binds to Toll-like receptors 7 and 8 and induces alpha-interferon. We locally applied imiquimod 5% cream (Aldara) daily for 2 weeks on a PUVA- and retinoid-resistant plaque on the face of a patient with mycosis fungoides. The diagnosis was based on clinical appearance, histology and molecular studies. Most of the disease manifestations showed a clear remission during PUVA therapy combined with low-dose retinoids. However, the plaque on the face was PUVA resistant. Local imiquimod treatment resulted in the complete clearance of the plaque. The patient has now been in complete remission for 12 months.
咪喹莫特是一种局部免疫反应调节剂，它与Toll样受体7和8结合并诱导α-干扰素。我们对一名蕈样肉芽肿患者面部一块对补骨脂素紫外线A光化学疗法（PUVA）和维甲酸耐药的斑块，每天局部应用5%咪喹莫特乳膏（艾达乐），持续2周。诊断基于临床表现、组织学和分子研究。大多数疾病表现经PUVA疗法联合低剂量维甲酸治疗后明显缓解。然而，面部的斑块对PUVA耐药。局部应用咪喹莫特治疗使斑块完全消退。该患者现已完全缓解12个月。
